Filing Flows › Companies › Collegium Pharmaceutical › Timeline
Collegium Pharmaceutical stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−40.5% to $24.21
Collegium Pharmaceutical (COLL) stock fell 40% over the last 252 sessions, to $24.21. On the way it reported 5 quarters, its insiders filed 5 open-market trades and 3 Form 144 notices of planned sales, and the company filed 5 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 5, 2026 | Earnings | Earnings: beat the EPS estimate by 5.6% | +6.1% (+10.6% vs SPY) | — | — |
| Oct 19, 2026 | 8-K | Termination of a material agreement | +0.9% (+0.6% vs SPY) | +0.9% (+1.0% vs SPY) | — |
| Sep 30, 2026 | Form 144 | Form 144: Scott Dreyer plans to sell $603K | −1.9% (−1.6% vs SPY) | −1.6% (−3.5% vs SPY) | +4.4% (+3.4% vs SPY) |
| Aug 6, 2026 | Earnings | Earnings: beat the EPS estimate by 8.8% | −20.5% (−20.4% vs SPY) | −33.0% (−33.3% vs SPY) | −41.1% (−41.5% vs SPY) |
| Jul 17, 2026 | Form 144 | Form 144: John A. Fallon plans to sell $497K | −0.5% (+0.5% vs SPY) | −1.9% (−0.2% vs SPY) | −25.1% (−28.4% vs SPY) |
| Jul 15, 2026 | Form 144 | Form 144: John A. Fallon plans to sell $294K | +4.7% (+4.3% vs SPY) | +2.3% (+2.8% vs SPY) | −31.0% (−33.7% vs SPY) |
| May 15, 2026 | Insider sale | Freund John Gordon sold $143K | −3.1% (−1.8% vs SPY) | −1.2% (−0.5% vs SPY) | −1.8% (−2.8% vs SPY) |
| May 13, 2026 | Insider sale | Lurker Nancy sold $162K | −2.3% (−2.9% vs SPY) | −6.0% (−5.4% vs SPY) | −3.8% (−3.8% vs SPY) |
| May 12, 2026 | 8-K | Completed acquisition or disposition | −0.3% (−0.2% vs SPY) | −6.2% (−6.1% vs SPY) | −2.8% (−1.0% vs SPY) |
| May 11, 2026 | Insider sale | Bohlin Garen G sold $323K | −5.4% (−5.6% vs SPY) | −11.2% (−11.5% vs SPY) | −9.4% (−9.4% vs SPY) |
| May 7, 2026 | Earnings | Earnings: beat the EPS estimate by 15.5% | +7.4% (+7.7% vs SPY) | −4.6% (−5.7% vs SPY) | −9.0% (−9.5% vs SPY) |
| Apr 7, 2026 | 8-K | Directors and officers: departures, appointments, pay | +2.0% (−0.5% vs SPY) | +8.4% (+3.2% vs SPY) | +10.8% (+0.1% vs SPY) |
| Mar 19, 2026 | 8-K | Material definitive agreement | −2.4% (−1.0% vs SPY) | −8.3% (−6.3% vs SPY) | −5.7% (−13.1% vs SPY) |
| Feb 26, 2026 | Earnings | Earnings: missed the EPS estimate by -4.7% | −3.4% (−2.8% vs SPY) | −14.4% (−13.2% vs SPY) | −31.4% (−24.5% vs SPY) |
| Dec 30, 2025 | 8-K | Material definitive agreement | −4.9% (−4.8% vs SPY) | −6.8% (−7.4% vs SPY) | −8.7% (−9.6% vs SPY) |
| Dec 5, 2025 | Insider sale | Balice-Gordon Rita J. sold $172K | +1.0% (+0.8% vs SPY) | +2.0% (+1.3% vs SPY) | −2.6% (−4.0% vs SPY) |
| Nov 12, 2025 | Insider sale | Fallon John A. sold $1.6M | +5.4% (+5.4% vs SPY) | +1.1% (+4.5% vs SPY) | +7.6% (+6.7% vs SPY) |
| Nov 6, 2025 | Earnings | Earnings: beat the EPS estimate by 21.0% | +12.6% (+13.7% vs SPY) | +27.8% (+27.0% vs SPY) | +29.0% (+27.8% vs SPY) |
Insiders’ record here
In the year on the chart, Collegium Pharmaceutical's insiders reported 0 open-market buys ($0) and 5 sales ($2.4M). Of the 5 old enough to score, 5 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −22.3%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 1.02 Termination of a material agreement | 2,368 | 0.0% | 51% | +1.1% | ±1.5% |
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 2.01 Completed acquisition or disposition | 2,671 | +0.1% | 52% | +1.2% | ±1.6% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Collegium Pharmaceutical: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.